{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:43Z","timestamp":1793401183955,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer Consumer Care AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03553-z","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:11:34Z","timestamp":1774685494000},"page":"2439-2457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of Aflibercept 8\u00a0mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison"],"prefix":"10.1007","volume":"43","author":[{"given":"Paolo A.","family":"Cortesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Mezghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alshaikheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Lunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Fazzi","family":"D\u2019Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Zurria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"8","key":"3553_CR1","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-016-3974-8","volume":"59","author":"B Bahrami","year":"2016","unstructured":"Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594\u2013608.","journal-title":"Diabetologia"},{"issue":"3","key":"3553_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"key":"3553_CR3","unstructured":"Wong TY, Yau J, Rogers SL, editors. Global prevalence of diabetic retinopathy: pooled data from population studies from the United States, Australia, Europe and Asia (poster). ARVO (May\u00a01\u20135, 2011); 2011; Fort Lauderdale, FL."},{"issue":"1","key":"3553_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10654-019-00560-z","volume":"35","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(1):11\u201323.","journal-title":"Eur J Epidemiol"},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"3627465","DOI":"10.1155\/2016\/3627465","volume":"2016","author":"S Vujosevic","year":"2016","unstructured":"Vujosevic S, Midena E. Diabetic retinopathy in Italy: epidemiology data and telemedicine screening programs. J Diabetes Res. 2016;2016:3627465.","journal-title":"J Diabetes Res"},{"issue":"7","key":"3553_CR6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1185\/03007995.2010.482503","volume":"26","author":"E Chen","year":"2010","unstructured":"Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7):1587\u201397.","journal-title":"Curr Med Res Opin"},{"key":"3553_CR7","doi-asserted-by":"publisher","first-page":"632307","DOI":"10.1155\/2014\/632307","volume":"2014","author":"FR Stefanini","year":"2014","unstructured":"Stefanini FR, Badaro E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014:632307.","journal-title":"J Immunol Res"},{"issue":"1","key":"3553_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ceo.12999","volume":"46","author":"GC Cheung","year":"2018","unstructured":"Cheung GC, Yoon YH, Chen LJ, et al. Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. Clin Experiment Ophthalmol. 2018;46(1):75\u201386.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"4","key":"3553_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185\u2013222.","journal-title":"Ophthalmologica"},{"issue":"2","key":"3553_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS, Cheung N, Sim\u00f3 R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3553_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608\u201322.","journal-title":"Ophthalmology"},{"issue":"1","key":"3553_CR12","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern\u00ae. Ophthalmology. 2020;127(1):P66\u2013P145.","journal-title":"Ophthalmology"},{"key":"3553_CR13","unstructured":"European Medicines Agency. Summary of Product Characteristics. Lucentis (ranibizumab): European Medicines Agency (EMA); 2022 [updated 11\/10\/2022]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lucentis]. Accessed October 30, 2025."},{"key":"3553_CR14","unstructured":"European Medicines agency. Summary of Product Characteristics. Beovu (brolucizumab): European Medicines Agency (EMA); 2022 [updated 06\/04\/2022]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beovu-epar-product-information_en.pdf]. Accessed October 30, 2025."},{"key":"3553_CR15","unstructured":"European Medicines Agency. Summary of Product Characteristics. Vabysmo (faricimab): European Medicines Agency (EMA); 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf]. Accessed October 30, 2025."},{"key":"3553_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/DMSO.S214098","volume":"12","author":"KL Spooner","year":"2019","unstructured":"Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1913\u201321.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"10 Suppl","key":"3553_CR17","first-page":"s284","volume":"22","author":"NM Holekamp","year":"2016","unstructured":"Holekamp NM. Overview of diabetic macular edema. Am J Manag Care. 2016;22(10 Suppl):s284\u201391.","journal-title":"Am J Manag Care"},{"issue":"4","key":"3553_CR18","doi-asserted-by":"publisher","first-page":"e14746","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39(4):e14746.","journal-title":"Diabet Med"},{"issue":"1","key":"3553_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40942-021-00311-x","volume":"7","author":"S M\u00fcller","year":"2021","unstructured":"M\u00fcller S, Junker S, Wilke T, et al. Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT. Int J Retina Vitreous. 2021;7(1):43.","journal-title":"Int J Retina Vitreous"},{"issue":"6","key":"3553_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00417-020-04944-w","volume":"259","author":"MS Ramakrishnan","year":"2021","unstructured":"Ramakrishnan MS, Yu Y, VanderBeek BL. Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet Protocol T. Graefes Arch Clin Exp Ophthalmol. 2021;259(6):1419\u201325.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"3553_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/bjophthalmol-2020-316514","volume":"106","author":"D Jaggi","year":"2022","unstructured":"Jaggi D, Nagamany T, Ebneter A, Munk M, Wolf S, Zinkernagel M. Aflibercept for age-related macular degeneration: 4-year outcomes of a \u2018treat-and-extend\u2019 regimen with exit-strategy. Br J Ophthalmol. 2022;106(2):246\u201350.","journal-title":"Br J Ophthalmol"},{"issue":"10432","key":"3553_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase\u00a02\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"key":"3553_CR23","unstructured":"Do DV, Wykoff CC, Sivaprasad S, et al. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2\/3 PHOTON Trial. Ophthalmology. Published online November 10, 2025. https:\/\/www.aaojournal.org\/article\/S0161-6420(25)00707-9\/fulltext. Accessed November 11, 2025."},{"issue":"8","key":"3553_CR24","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1007\/s12325-025-03233-4","volume":"42","author":"SW Quist","year":"2025","unstructured":"Quist SW, Paulissen JHJ, Lunk I, et al. Anti-VEGFs for diabetic macular oedema: analysis of efficacy, safety, and cost of more durable therapies from a Dutch societal perspective. Adv Ther. 2025;42(8):3774\u201394.","journal-title":"Adv Ther"},{"issue":"11","key":"3553_CR25","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s40123-025-01247-3","volume":"14","author":"SM Friedman","year":"2025","unstructured":"Friedman SM, Xu Y, Sherman S, et al. Aflibercept 8\u00a0mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials. Ophthalmol Ther. 2025;14(11):2919\u201336.","journal-title":"Ophthalmol Ther"},{"key":"3553_CR26","first-page":"311","volume":"107","author":"PK Kaiser","year":"2009","unstructured":"Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311\u201324.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"8","key":"3553_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: two-year results from the phase\u00a03 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year\u00a02. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"6","key":"3553_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase\u00a03 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"4","key":"3553_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"key":"3553_CR30","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment: ScHARR; 2012. www.ncbi.nlm.nih.gov\/books\/NBK395886\/pdf\/Bookshelf_NBK395886.pdf. Accessed October 30, 2024."},{"issue":"3","key":"3553_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.survophthal.2007.02.010","volume":"52","author":"AM Joussen","year":"2007","unstructured":"Joussen AM, Lehmacher W, Hilgers RD, Kirchhof B. Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration. Surv Ophthalmol. 2007;52(3):266\u201378.","journal-title":"Surv Ophthalmol"},{"key":"3553_CR32","unstructured":"R Core Team. A language and environment for statistical computing 2021. https:\/\/www.r-project.org\/. Accessed October 30, 2024."},{"key":"3553_CR33","unstructured":"Van Valkenhoef G, Kuiper J. Network Meta-Analysis Using Bayesian Methods (Package \u2018gemtc\u2019) 2023. https:\/\/cran.r-project.org\/web\/packages\/gemtc\/gemtc.pdf. Accessed October 30, 2024."},{"issue":"6","key":"3553_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3102\/1076998616664876","volume":"41","author":"S Depaoli","year":"2016","unstructured":"Depaoli S, Clifton JP, Cobb PR. Just another Gibbs sampler (JAGS): flexible software for MCMC implementation. J Educ Behav Stat. 2016;41(6):628\u201349.","journal-title":"J Educ Behav Stat"},{"issue":"1","key":"3553_CR35","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1080\/13696998.2025.2536420","volume":"28","author":"A Ambresin","year":"2025","unstructured":"Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. J Med Econ. 2025;28(1):1198\u2013213.","journal-title":"J Med Econ"},{"key":"3553_CR36","unstructured":"Wailoo A, Dixon S. The use of cost minimisation analysis for the appraisal of health technologies: ScHARR; 2019. https:\/\/www.sheffield.ac.uk\/media\/33949\/download?attachment. Accessed October 30, 2024."},{"key":"3553_CR37","unstructured":"Aflibercept for treating diabetic macular oedema. Technology appraisal guidance [TA346]: National Institute for Health and Care Excellence (NICE); 2015. https:\/\/www.nice.org.uk\/guidance\/ta346\/resources\/aflibercept-for-treating-diabetic-macular-oedema-pdf-82602611201221]. Accessed October 30, 2025."},{"key":"3553_CR38","unstructured":"NICE. Faricimab for treating diabetic macular oedema 2022. https:\/\/www.nice.org.uk\/guidance\/ta799. Accessed October 30, 2025."},{"key":"3553_CR39","unstructured":"NICE. Dexamethasone intravitreal implant for treating diabetic macular oedema 2022. https:\/\/www.nice.org.uk\/guidance\/ta824. Accessed October 30, 2025."},{"issue":"1","key":"3553_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12913-022-07972-w","volume":"22","author":"N Ferrante","year":"2022","unstructured":"Ferrante N, Ritrovato D, Bitonti R, Furneri G. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv Res. 2022;22(1):573.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"3553_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1474515120944014","volume":"19","author":"T Ruppar","year":"2020","unstructured":"Ruppar T. Meta-analysis: how to quantify and explain heterogeneity? Eur J Cardiovasc Nurs. 2020;19(7):646\u201352.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"1","key":"3553_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40942-022-00385-1","volume":"8","author":"CQ Felipe","year":"2022","unstructured":"Felipe CQ, Biancardi AL, Civile VT, Carvas Junior N, Serracarbassa PD, Koike MK. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retina Vitreous. 2022;8(1):34.","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"3553_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11892-012-0283-6","volume":"12","author":"J Ding","year":"2012","unstructured":"Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346\u201354.","journal-title":"Curr Diab Rep"},{"issue":"2","key":"3553_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234\u201347.","journal-title":"Ophthalmology"},{"issue":"6","key":"3553_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"issue":"8","key":"3553_CR46","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s40123-025-01180-5","volume":"14","author":"D Tabano","year":"2025","unstructured":"Tabano D, Watane A, Gale R, et al. The economic burden of anti-vascular endothelial growth factor on patients and caregivers in the UK, Europe, and North America. Ophthalmol Ther. 2025;14(8):1869\u201392.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"3553_CR47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, et al. Efficacy, safety, and injection frequency with novel aflibercept 8\u00a0mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a bayesian network meta-analysis. Ophthalmol Ther. 2025;14(4):733\u201353.","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"3553_CR48","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","volume":"130","author":"R Rajendram","year":"2012","unstructured":"Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972\u20139.","journal-title":"Arch Ophthalmol"},{"key":"3553_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE phase\u00a03 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2024;260:70\u201383.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3553_CR50","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","volume":"39","author":"JG Garweg","year":"2022","unstructured":"Garweg JG, Stefanickova J, Hoyng C, et al. Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial. Adv Ther. 2022;39(6):2701\u201316.","journal-title":"Adv Ther"},{"issue":"10","key":"3553_CR51","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044\u201352.","journal-title":"Ophthalmology"},{"issue":"6","key":"3553_CR52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/IAE.0000000000002114","volume":"39","author":"M Lafuente","year":"2019","unstructured":"Lafuente M, Ortin L, Argente M, et al. Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema. Retina. 2019;39(6):1083\u201390.","journal-title":"Retina"},{"issue":"6","key":"3553_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"C Pr\u00fcnte","year":"2016","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5\u00a0mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787\u201395.","journal-title":"Br J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03553-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:08Z","timestamp":1780120988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03553-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Francesco Bandello consults for Abbvie, Adverum Biotechnologies Inc., Alimera, Apellis, Bayer, Boehringer Ingelheim, Breye Therapeutics A.p.S., Fidia Sooft, Hoffmann-La Roche, Outlook Therapeutics, Novartis, NTC Pharma, Oxurion NV, 4D Molecular Therapeutics Inc., SIFI. Prof. Paolo Angelo Cortesi has received grants and personal fees from Hoffmann-La Roche, Almirall, Otsuka, Novartis, Daiichi Sankyo, Boehringer Ingelheim, and Bayer. Izabella Lunk, Mario Fazzi D\u2019Orsi, and Monica Zurria are employees of Bayer. Marwa Mezghani and Mohammed Alshaikheid\u00a0declare that they were employed by Putnam at the time the research was conducted, a company which received funds from Bayer to conduct this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}